Contineum Therapeutics (CTNM) Total Non-Current Liabilities (2023 - 2024)

Contineum Therapeutics (CTNM) recorded quarterly Total Non-Current Liabilities of $14.8 million in Q4 2024, up 154.58% quarter-over-quarter from $5.8 million in Q3 2024, and up 164.32% on a YoY basis from $5.6 million in Q1 2024.

Contineum Therapeutics (CTNM) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends

Contineum Therapeutics' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $14.8 million for Q4 2024.

  • In Q4 2024, Total Non-Current Liabilities rose 164.32% year-over-year to $14.8 million; the TTM figure through Dec 2024 stood at $14.8 million (up 164.32% YoY), while the FY2024 annual figure was $14.8 million, up 164.32% from the prior year.
  • Total Non-Current Liabilities was $14.8 million for Q4 2024 at Contineum Therapeutics, up from $5.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $14.8 million in Q4 2024 to a low of $3.9 million in Q2 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - 42,980.09
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - 11.03 Mn
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 95.20 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -
7 Psyence Biomedical 227.32 Bn 227.31 Bn - 644,700.00
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn 5.87 Bn
9 Abivax 91.71 Bn 91.71 Bn - 64.76 Mn
10 Contineum Therapeutics 423.05 Mn 423.05 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 14.78 Mn
Sep 30, 2024 5.81 Mn
Jun 30, 2024 3.85 Mn
Mar 31, 2024 6.35 Mn
Dec 31, 2023 5.59 Mn